Controlled-release and stratified cyclodextrin inclusion complex vehicles
AssigneeCZAP Research and Development LLC
InventorAl CZAP
Life of this patent
Estimating the term…
Abstract
The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.
Claims57
A cyclodextrin inclusion complex delivery vehicle, comprising:
- a cyclodextrin having a cavity;
- a biologically active molecule that is at least partially retained as a guest molecule within the cavity of the cydodextrin, forming a cyclodextrin inclusion complex;
- a biologically acceptable carrier for the cyclodextrin inclusion complex, wherein the guest molecule is stably retained by the cyclodextrin within the biologically acceptable carrier;
- and,
- an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the guest molecule, wherein the enzyme is formulated so that the cyclodextrin-degrading activity is activated on delivery of the vehicle to a target so as to release the guest molecule from the cyclodextrin cavity.
A method of formulating a cyclodextrin inclusion complex delivery vehicle, comprising:
- providing a cyclodextrin having a cavity;
- providing a biologically active molecule that is at least partially retained as a guest molecule within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
- providing a biologically acceptable carrier for the cydodextrin inclusion complex, wherein the guest molecule is stably retained by the cyclodextrin within the biologically acceptable carrier, and,
- providing an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the guest molecule, wherein the enzyme is co-formulated with the cyclodextrin inclusion complex so that the cyclodextrin-degrading activity is activated on delivery of the vehicle to a target so as to release the guest molecule from the cyclodextrin cavity.
A pharmaceutical formulation comprising acetaminophen and an N-acetylcysteine cyclodextrin inclusion complex in a pharmaceutically acceptable carrier.
A method of formulating acetaminophen, comprising combining acetaminophen and an N-acetylcysteine cydodextrin inclusion complex in a pharmaceutically acceptable carrier.
A meal replacement or elemental diet formulation comprising an amino acid in a cyclodextrin inclusion complex, wherein the amino acid is one or more of L-phenylalanine, N-acetyl-cysteine, L-cysteine, L-methionine, L-isoleucine or L-tryptophan.
A multicomponent stacked cyclodextrin inclusion complex comprising:
- A cyclodextrin having a cavity;
- an amino acid that is retained as a first guest molecule within the cavity of the cyclodextrin;
- and,
- a biologically acceptable lipid that is at least partially retained as a second guest molecule within the cavity of the cyclodextrin.
A multicomponent stacked cyclodextrin inclusion complex comprising:
- A cyclodextrin having a cavity;
- N-actyl-cysteine at least partially retained as a first guest molecule within the cavity of the cyclodextrin;
- and,
- acetaminophen at least partially retained as a second guest molecule within the cavity of the cyclodextrin.
A method of treating a patient having autism spectrum disorder, comprising administering to the patient an effective amount of a short chain fatty acid cyclodextrin inclusion complex.
A method for modulating the microbiome of a patient having a neurological diseases, comprising administering to the patient an effective amount of a short chain fatty acid cyclodextrin inclusion complex.
Dependencies are inferred from the claim text.